EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

The current status of gene expression profilings in COVID‐19 patients

Mirolyuba Ilieva iD, Max Tschaikowski, Andrea Vandin, Shizuka Uchida iD

Clinical and Translational Discovery · 2022

DOI: 10.1002/ctd2.104 ↗

At a glance

Journal article in Clinical and Translational Discovery, 2022. Written by Mirolyuba Ilieva and 3 co-authors. Institution: Center for RNA Medicine, Department of Clinical Medicine Aalborg University Copenhagen Denmark. Cited 20 times so far (Crossref); 29 references. The full text is freely available (open access, CC BY 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

The global pandemic of coronavirus disease 2019 (COVID‐19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has swept through every part of the world. Because of its impact, international efforts have been underway to identify the variants of SARS‐CoV‐2 by genome sequencing and to understand the gene expression changes in COVID‐19 patients compared to healthy donors using RNA sequencing (RNA‐seq) assay. Within the last two and half years since the emergence of SARS‐CoV‐2, a large number of OMICS data of COVID‐19 patients have accumulated. Yet, we are still far from understanding the disease mechanism. Further, many people suffer from long‐term effects of COVID‐19; calling for a more systematic way to data mine the generated OMICS data, especially RNA‐seq data.

Methods

By searching gene expression omnibus (GEO) using the key terms, COVID‐19 and RNA‐seq, 108 GEO entries were identified. Each of these studies was manually examined to categorize the studies into bulk or single‐cell RNA‐seq (scRNA‐seq) followed by an inspection of their original articles.

Results

The currently available RNA‐seq data were generated from various types of patients’ samples, and COVID‐19 related sample materials have been sequenced at the level of RNA, including whole blood, different components of blood [e.g., plasma, peripheral blood mononuclear cells (PBMCs), leukocytes, lymphocytes, monocytes, T cells], nasal swabs, and autopsy samples (e.g., lung, heart, liver, kidney). Of these, RNA‐seq studies using whole blood, PBMCs, nasal swabs and autopsy/biopsy samples were reviewed to highlight the major findings from RNA‐seq data analysis.

Conclusions

Based on the bulk and scRNA‐seq data analysis, severe COVID‐19 patients display shifts in cell populations, especially those of leukocytes and monocytes, possibly leading to cytokine storms and immune silence. These RNA‐seq data form the foundation for further gene expression analysis using samples from individuals suffering from long COVID.

Subjects

Author keywords

COVID‐19RNA‐seqbiomarkergene expression

Authors and institutions

  • Center for RNA Medicine, Department of Clinical Medicine Aalborg University Copenhagen Denmark.
  • Department of Computer Science Aalborg University Aalborg Denmark.
  • Institute of Economics and EMbeDS Sant'Anna School of Advanced Studies Pisa Italy.
  • Department of Applied Mathematics and Computer Science Technical University of Denmark Kongens Lyngby Denmark.

ORCID profiles: Mirolyuba Ilieva, Shizuka Uchida

Cite

APA

Ilieva, M., Tschaikowski, M., Vandin, A., & Uchida, S. (2022). The current status of gene expression profilings in COVID‐19 patients. Clinical and Translational Discovery. https://doi.org/10.1002/ctd2.104

Vancouver

Ilieva M, Tschaikowski M, Vandin A, Uchida S. The current status of gene expression profilings in COVID‐19 patients. Clinical and Translational Discovery. 2022. doi:10.1002/ctd2.104

BibTeX
@article{Ilieva2022,
  author = {Ilieva, Mirolyuba and Tschaikowski, Max and Vandin, Andrea and Uchida, Shizuka},
  title = {The current status of gene expression profilings in COVID‐19 patients},
  journal = {Clinical and Translational Discovery},
  year = {2022},
  doi = {10.1002/ctd2.104}
}
Start for free →